Posted by Michael Wonder on 16 Jan 2020
Breast cancer patients to have further NICE approved drug combination option on Cancer Drugs Fund
15 January 2020 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund following its approval by NICE in final guidance published today.
The guidance recommends palbociclib (also called Ibrance and made by Pfizer) given with fulvestrant for people with a type of advanced breast cancer called hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have already had endocrine therapy.
Palbociclib joins 2 other NICE-approved drugs – ribociclib and abemaciclib – this stage of treatment. Taken once-daily in pill form, palbociclib is a type of drug called a cyclin-dependent kinase 4 and 6 inhibitor.
